The PTN study of the safety and pharmacokinetics of lisinopril in pediatric kidney transplant recipients will begin enrolling patients at the end of April. At that time, 4 of the anticipated 8 sites should be activated.
Lisinopril use is FDA-approved in children aged 6+ years for the treatment of high blood pressure, a condition that is common among children and adolescents who receive kidney transplants. Unfortunately, the appropriate dose of lisinopril in these especially vulnerable patients is not currently known.
Enrolling sites in the PTN lisinopril study will eventually include: Albert Einstein University Hospital in New York, Cincinnati Children’s Hospital, Children’s Mercy Hospital in Kansas City, Emory University & Children’s Healthcare of Atlanta, University of Alabama–Birmingham, Arkansas Children’s Hospital in Little Rock, University of Michigan at Ann Arbor, and New York University Langone Medical Center.
This study will evaluate the safety of oral lisinopril in pediatric participants who have a stable functioning kidney transplant and high blood pressure. It will also examine what young bodies do to the drug (a.k.a. the drug’s pharmacokinetics). The trial team plans to recruit a total of 24–28 children ages 2–17 years.